Journal
CagriSema: Novo's Next Act — the Amylin Combination and Its Roughly 23% Result
Released: Last reviewed:
The short answer
CagriSema is Novo Nordisk's escalation: weekly semaglutide 2.4 mg co-formulated with cagrilintide 2.4 mg, an amylin analog — a second satiety hormone pathway stacked on the GLP-1 — whose phase-3 REDEFINE-1 readout showed roughly 22.7% average loss at 68 weeks in the primary analysis: ahead of semaglutide alone (14.9%) and of tirzepatide's 20.9% arm on cross-trial squinting, yet famously short of the ~25% Novo had guided markets to expect, a miss that moved share prices more than science. REDEFINE-2 added a T2D result in the mid-teens. Status: not approved, not purchasable — regulatory submissions and further readouts are the 2026 story — and the standing warning inherits from retatrutide's page verbatim: anything sold today as "CagriSema," "cagrilintide," or an amylin blend is gray-market research chemistry with no legal compounding lane and no place in a rational plan — the FDA's "Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" page (current as of October 1, 2026) states that cagrilintide cannot be used in compounding under federal law.
Why amylin, and what to do meanwhile
The mechanism bet: amylin is the pancreas's co-released satiety signal — slowing gastric emptying and acting on brainstem appetite circuits through different receptors than GLP-1 — so combining analogs of both aims at additive appetite control without simply raising one pathway's dose and its side effects. The readout's nuance worth keeping: trial-conduct details (flexible dosing protocols, adherence patterns) muddied the headline enough that analysts argued the molecule's ceiling remains unproven in either direction — a genuinely open scientific question the confirmatory program will answer. The practical translation for a 2026 buyer is the pipeline pages' constant refrain: today's approved tools already deliver 15–21% studied results at prices this site tracks daily; waiting for a marginally better drug costs a year of treatable months, and switching later is routine. Watch the space through the pipeline tracker; treat any current "CagriSema source" as the scam it is; and let the only medicine you take be the kind with a label.
Questions people ask
What is CagriSema and how well does it work?
Novo's phase-3 combination of semaglutide 2.4 mg with cagrilintide 2.4 mg (an amylin analog): REDEFINE-1 reported roughly 22.7% average loss at 68 weeks — ahead of semaglutide alone, short of Novo's ~25% target. A T2D trial added mid-teens results. It is not yet approved or purchasable.
When will CagriSema be available?
Regulatory submissions and confirmatory readouts are the current phase; availability follows approval, which hasn't happened. Timelines are the manufacturer's to announce — and any seller offering it today is offering unregulated research chemistry, not the drug.
Can I buy cagrilintide from peptide sites now?
Only as gray-market research chemicals — no approval, no legal compounding lane, no quality oversight, unknown dosing safety. The rational 2026 move is an approved 15–21% drug today (at prices from $129–$449 across our rankings) and a routine switch later if the combination earns it.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.